Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.
about
Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreakStandard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisCombination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisStandard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisStandard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisCombination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosisAntimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisTreatments for preventing recurrence of infection withPseudomonas aeruginosain people with cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisTobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisClinical applications of pulmonary delivery of antibioticsModular Approach to Select Bacteriophages Targeting Pseudomonas aeruginosa for Their Application to Children Suffering With Cystic FibrosisUse of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosisInitial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosisInfluenza vaccination in children with cystic fibrosis.Nonparametric estimation of the mean function for recurrent event data with missing event category.Comparison of the sensitivity of culture, PCR and quantitative real-time PCR for the detection of Pseudomonas aeruginosa in sputum of cystic fibrosis patients.Nonparametric association analysis of bivariate left-truncated competing risks data.Uncovering symptom progression history from disease registry data with application to young cystic fibrosis patients.Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis.Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis.Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.Staphylococcus aureus serves as an iron source for Pseudomonas aeruginosa during in vivo cocultureInfluenza-associated cystic fibrosis pulmonary exacerbations.Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysisPseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatmentThe changing microbial epidemiology in cystic fibrosis.Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis.Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.The microbiome in pediatric cystic fibrosis patients: the role of shared environment suggests a window of intervention.Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.Pseudomonas aeruginosa AES-1 exhibits increased virulence gene expression during chronic infection of cystic fibrosis lung.Quantile regression for doubly censored data.Pseudomonas aeruginosa in children with cystic fibrosis diagnosed through newborn screening: assessment of clinic exposures and microbial genotypes
P2860
Q22306482-3C778371-C0D9-45A6-8270-E4C5BEEB3E93Q24187383-5E872586-87EC-4DFB-A5F3-84BE38E532C7Q24188024-6BEAF4CA-4E99-4AE5-B1EC-2D882BDDEA9FQ24188054-C3400067-464F-49DF-89C8-5444A371FC7BQ24202879-AC454DF7-6E51-4FBC-90AF-4BC94892355FQ24203005-FA5799BC-CA2E-4364-9873-F7B1FA426B18Q24234955-96DD4ACD-5B8D-4A0D-92FB-594E860F6431Q24240388-A1CFD098-460C-46D5-BFE4-72A5FE51004BQ24242073-662E3FB4-4FF2-4112-BE26-87B490FEBE09Q24243047-1599C50A-8F7D-401E-A228-24511BE6DEB5Q24243916-D53A5E14-881C-4470-AA60-1C991D82B4D7Q26470661-AE55FD54-B949-4CCD-9F40-31B9EDFC7B7EQ26471106-DC4A3E3D-5431-4A88-9CC2-68C725B5187CQ26829604-2AD4393A-C3F1-498F-BB81-DB61A6C5CFDDQ26996053-DB991EDC-CB3E-4A4C-A48B-69A3740464B2Q28076246-3FF9831E-B5D9-4BC8-8604-DADC0BBD6E23Q30238814-19D95644-7C8E-4A91-840D-D3022238109FQ30412485-A89B158D-19DE-4867-A541-E2A3138ADF32Q30422695-A44F1839-1078-4F61-8BB4-0533644CAA4BQ30429062-EC22856E-685E-47B4-A272-8F78D8221336Q30731623-E8B32079-2BD4-4862-8FF8-D6ACF94280DEQ30924268-018F908E-9CB7-4531-8CD9-58DB19EA0F5BQ31019408-778C51D5-DD9B-4238-8655-56254CADFF5EQ33467002-C7D05818-FED5-4D86-B3DC-80262FAC866AQ33474273-E8E57A50-1292-47F6-BDD5-FA2EB09B76B8Q33592546-718E010B-BF3A-46D2-8497-90DBF0FF8FCFQ33688123-2BB1BD5C-A157-49D2-895B-F432CFCACF4BQ33699922-43BF0332-A582-4E2A-83EC-7D7E66DA2BC2Q33776832-D622A6F0-1D32-4D23-9203-3294D604A2DEQ33811280-84A84471-17C1-4F67-B384-170D089CEC95Q33824149-47275692-F4C3-425B-A381-6C6B91ED7B60Q33825634-292EE3F2-69E8-48FB-AC9C-CB06097C682BQ33861117-09C4DD7B-991C-4A9D-9835-DDC76579E6EBQ33869527-8DA8EEA9-6281-4F00-8EF5-98E801B8299FQ33957168-3EAAAC32-E903-417C-886C-80D410ABEB8EQ33960112-2F1D111C-8AFF-40BB-BC49-EDFFBBA23C3BQ34016539-4C647703-B681-4AA0-9F97-2049BECFC3C5Q34026130-50922004-46B4-4BE7-A92A-2C7F5AD20547Q34032169-678BA25A-BF9A-4484-A0FD-B0C5DA242204Q34067203-5CB1F166-FF74-4C61-AC48-B8F40A10B53C
P2860
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Acceleration of lung disease i ...... omonas aeruginosa acquisition.
@en
Acceleration of lung disease i ...... omonas aeruginosa acquisition.
@nl
type
label
Acceleration of lung disease i ...... omonas aeruginosa acquisition.
@en
Acceleration of lung disease i ...... omonas aeruginosa acquisition.
@nl
prefLabel
Acceleration of lung disease i ...... omonas aeruginosa acquisition.
@en
Acceleration of lung disease i ...... omonas aeruginosa acquisition.
@nl
P2093
P356
P1476
Acceleration of lung disease i ...... omonas aeruginosa acquisition.
@en
P2093
Farrell PM
Kosorok MR
Splaingard ML
P304
P356
10.1002/PPUL.2009.ABS
P577
2001-10-01T00:00:00Z